-
1
-
2
-
3
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
4
-
5
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
6
-
7
-
8
-
9
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
10
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
11
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
12
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
13
-
14
-
15
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
16
-
17
-
18
HFD decreases intermediate-term memory.
Published 2025“…<p>(A) The survival rate of 10d <i>Canton-S</i> fed with ND or HFD was observed for 7 days. There was no significant decline in the survival rate in flies fed with HFD compared with ND (n = 10 vials, containing 20 flies at each time point). …”
-
19
-
20
Analysis of the Nugent score before (T=0) and after (T=1) the use of the vaginal gel. Number of participants and respective percentages of Nugent scores before and after the intervention. A statistically significant decrease in Nugent scores was observed after the intervention (p value =0.0047).
Published 2025“…Number of participants and respective percentages of Nugent scores before and after the intervention. A statistically significant decrease in Nugent scores was observed after the intervention (p value =0.0047).…”